Novaremed
Switzerland - BaselBiotechnology
Focus: Novaremed is a newly founded (2024) Swiss biotech company focused on developing treatments for neuropathic pain in the neurology space. As a pre-revenue private company, it represents an early-stage venture with no disclosed funding or active pipeline data.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Funding Stage
PRIVATE
Open Jobs
0
About Novaremed
AI assessmentNot HiringNo open roles listed right now. Follow Novaremed to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
NRD135S.E1
Diabetic Peripheral Neuropathic PainClinical Trials (1)
NCT02345291Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients
Phase 2Help build intelligence for Novaremed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.